银屑病
伊米奎莫德
趋化因子
红斑
医学
白细胞介素17
免疫系统
免疫学
细胞因子
药理学
作者
Juan Wu,Shan Liu,Hongwei Zhang,Xingyue Zhang,Jie Xue,Zhengjuan Li,Yue Zhang,Yiming Jiang,Pengyan Zhang,Meng‐Lin Yang,Qinghua Cui,Guanhua Du,Lili Zhao
标识
DOI:10.1016/j.biopha.2025.117922
摘要
Psoriasis is a chronic inflammatory dermatological disorder characterized by the aberrant differentiation and hyperproliferation of epidermal keratinocytes, boosted immune cell infiltration, and cytokine and chemokine production. Patients with psoriasis experience persistent discomfort and their conditions remain incurable. Therefore, development of safe and effective treatments for psoriasis is critical. Amlexanox, a tricyclic amine carboxylic acid, has various pharmacological advantages in previous studies, including anti-inflammatory, anti-allergic, immunomodulatory, and metabolic properties. Here we used the imiquimod (IMQ)-induced animal model and interleukin 17 A (IL-17A) activated keratinocytes to examine the efficacy of amlexanox in the treatment of psoriasis. Immunological and histological analyses revealed that both topical and oral administration of amlexanox reduced psoriatic symptoms such as increased skin thickness, erythema, scale formation, and immune cell infiltration. In the IMQ-induced mouse model, amlexanox also reduced splenic Th17 cell counts and the production of IL-17/Th17-associated cytokines and chemokines. Furthermore, amlexanox inhibited nuclear factor-κB phosphorylation in IL-17 activated keratinocytes. These findings indicated that amlexanox effectively alleviated psoriatic symptoms through both oral and topical administration. We propose that amlexanox is a potent therapeutic candidate for the treatment of psoriasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI